2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 3110

Rab4A Is Required for Development of Tregs, Restricts Antiphospholipid Antibody Production and Pro-Inflammatory Expansion of Macrophages and Neutrophils, and Blocks Pristane-Induced Intra-Alveolar Hemorrhage in a Mouse Model of SLE
Abstract Number: 2351

Racial Differences in Magnetic Resonance Image-Based Three-Dimensional Bone Shape of the Knee: Data from the Osteoarthritis Initiative (OAI)
Abstract Number: 116

Racial Differences in Self-Reported Pain and Disability: A Longitudinal Study of Knee Osteoarthritis
Abstract Number: 2501

Radiographic Damage in Patients with RA Increases By 8.3% per Year Disease Duration, in the Era of Biologic Dmards. Results from the Scqm Cohort
Abstract Number: 154

Radiographic Knee Osteoarthritis in Patients Complaining of Knee Pain: Ultrasound Features
Abstract Number: 2350

Radiographic Outcomes from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee
Abstract Number: 716

Radiographic Progression and Changes in Inflammation and Structural Damage on Serial MRI Examinations over 5 Years in Patients with Ankylosing Spondylitis Treated with TNF-Alpha Inhibitors
Abstract Number: 588

Radiographic Progression Is Less Significant in Anti-Carbamylated Antibody-Positive Patients with Rheumatoid Arthritis (RA) Who Were Clinically Active and Under the Treatment with Biological Dmards
Abstract Number: 718

Radiographic Progression of Hip Arthritis in Patients with Ankylosing Spondylitis Treated with TNF Inhibitors
Abstract Number: 2534

Radiographic Remission in Patients with Seropositive RA at Ten Years after Diagnosis, Treated in a Real Life Setting
Abstract Number: 2353

Radiographic Variations in Hip Morphology Are Associated with Hip Symptoms: A Cross-Sectional Analysis of a Large Community-Based Cohort
Abstract Number: 428

Random Forest Models Using Electronic Health Record Data Are Predictive of One-Year Outcomes in Lupus Nephritis Patients Taking Mycophenolate Mofetil Induction Therapy
Abstract Number: 797

Randomized Clinical Trials of Systemic Lupus Erythematosus: Evaluating Differences in the Enrolled Populations
Abstract Number: 1709

Randomized, Double-Blind Study Comparing Chs-0214 with Etanercept (Enbrel) in Patients with Psoriasis and Psoriatic Arthritis
Abstract Number: 2008

Rapamycin Elicits Rapid and Lasting Improvement of Disease Activity through Blocking Pro-Inflammatory T Cell Lineage Specification in Patients with Active SLE

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].